Press release
Cytomegalovirus Infection Pipeline Outlook Report 2025: Key 15+ Companies and Breakthrough Therapies Shaping the Future Landscape
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Cytomegalovirus Infection Treatment Landscape @ Cytomegalovirus Infection Pipeline Outlook [https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Cytomegalovirus Infection Pipeline Report
* In August 2025, ModernaTX, Inc . announced a study is to evaluate the efficacy of mRNA 1647 vaccine in CMV-seronegative female participants and to evaluate the safety and reactogenicity of mRNA-1647 vaccine in all participants. The purpose of the Phase 3 extension substudy is to extend the observation period of the main study and to assess the longer-term immunogenicity, efficacy, and safety of the mRNA-1647 vaccine against primary CMV infection in healthy females who were CMV-seronegative at Baseline of the mRNA-1647-P301 main study (including participants who remain CMV-seronegative upon entry into the extension substudy and participants who seroconverted during the main study).
* In August 2025, Memorial Sloan Kettering Cancer Center conducted a study is to determine of letermovir (LTC) is effective at preventing Cytomegalovirus (CMV) infection from returning in people who have already had CMV infection after a bone marrow transplant.
* DelveInsight's Cytomegalovirus Infection pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Cytomegalovirus Infection treatment.
* The leading Cytomegalovirus Infection Companies such as Hoffmann-La Roche, ModernaTX, Inc., Helocyte, VBI Vaccines Inc., SpyBiotech Limited, Vir Biotechnology, Inc., GlaxoSmithKline, and EVAXION BIOTECH A/S and others.
* Promising Cytomegalovirus Infection Pipeline Therapies such as Valganciclovir, V160, Letermovir, MCMV3068A, Maribavir, mRNA-1647, Ganciclovir, Brincidofovir, and others.
Discover groundbreaking developments in Cytomegalovirus Infection Therapies! Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Cytomegalovirus Infection Clinical Trials Assessment [https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Cytomegalovirus Infection Emerging Drugs Profile
* mRNA-1647: ModernaTX, Inc.
mRNA-1647 comprises six mRNAs encoding two antigens in one vaccine and is designed to protect against CMV infection. Of the six mRNAs, five encode the subunits of the CMV pentamer complex and one mRNA encodes the Glycoprotein B (gB) protein, both of which are highly immunogenic. The pentamer complex is important for CMV entry into a variety of cells, including epithelial cells, while gB is important for entry into all susceptible cells including fibroblasts. A vaccine that produces an immune response against both pentamer and gB has the potential to prevent CMV entry into a range of target cell types and thus prevent primary and congenital infections. Unlike a protein-based vaccine, mRNA-1647 instructs the body's own cells to manufacture the antigens, resulting in functional antigens that mimic those presented to the immune system by CMV during a natural infection. Preclinical data previously published in Vaccine showed that vaccination with mRNA-1647 in animal models elicited potent and durable neutralizing antibody titers. Currently, the drug is in Phase III stage of its development for the treatment of Cytomegalovirus (CMV) Infection.
* Cytomegalovirus vaccine (Triplex) : Helocyte
The Triplex vaccine by Helocyte is a multi-antigen vaccine designed to induce a robust and durable virus-specific T-cell response against cytomegalovirus (CMV) infections, particularly in recipients of allogeneic hematopoietic stem cell transplants (HSCT) and solid organ transplants (SOT). The vaccine utilizes the Modified Vaccinia Ankara (MVA) vector to express three immunodominant CMV proteins: UL83 (pp65), UL123 (IE1), and UL122 (IE2). By targeting these proteins, Triplex stimulates a host antiviral response, enhancing both CD4+ and CD8+ T-cell responses. This mechanism of action helps control CMV infections by promoting cellular immunity, which is crucial for managing and preventing CMV-related complications in immunocompromised patients.. Currently, the drug is in Phase II stage of its development for the treatment of Cytomegalovirus (CMV) Infection.
* VBI-1501: VBI Vaccines Inc.
VBI-1501 by VBI Vaccines Inc. is a prophylactic cytomegalovirus (CMV) vaccine candidate developed using the company's proprietary enveloped virus-like particle (eVLP) technology. This vaccine presents a modified form of the glycoprotein B (gB) found on CMV, which plays a crucial role in viral entry into host cells. The mechanism of action (MOA) of VBI-1501 involves inducing protective CMV-neutralizing antibodies that can block infection in multiple cell types, including fibroblasts and epithelial cells. By eliciting these antibodies, VBI-1501 aims to prevent CMV infection by mimicking the natural immune response observed in individuals who have developed immunity through natural infection. Currently, the drug is in Phase I stage of its development for the treatment of Cytomegalovirus (CMV) Infection.
The Cytomegalovirus Infection Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Cytomegalovirus Infection with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cytomegalovirus Infection Treatment.
* Cytomegalovirus Infection Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Cytomegalovirus Infection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cytomegalovirus Infection market
Stay informed about the Cytomegalovirus Infection pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Cytomegalovirus Infection Unmet Needs [https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Cytomegalovirus Infection Companies
Hoffmann-La Roche, ModernaTX, Inc., Helocyte, VBI Vaccines Inc., SpyBiotech Limited, Vir Biotechnology, Inc., GlaxoSmithKline, and EVAXION BIOTECH A/S and others.
Cytomegalovirus (CMV) Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Cytomegalovirus Infection Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Transform your understanding of the Cytomegalovirus Infection Pipeline! See the latest progress in drug development and clinical research @ Cytomegalovirus Infection Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Cytomegalovirus Infection Pipeline Report
* Coverage- Global
* Cytomegalovirus Infection Companies- Hoffmann-La Roche, ModernaTX, Inc., Helocyte, VBI Vaccines Inc., SpyBiotech Limited, Vir Biotechnology, Inc., GlaxoSmithKline, and EVAXION BIOTECH A/S and others.
* Cytomegalovirus Infection Pipeline Therapies- Valganciclovir, V160, Letermovir, MCMV3068A, Maribavir, mRNA-1647, Ganciclovir, Brincidofovir, and others.
* Cytomegalovirus Infection Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Cytomegalovirus Infection Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Infectious Diseases Research-Access the Full Cytomegalovirus Infection Pipeline Analysis Today! @ Cytomegalovirus Infection Drugs and Companies [https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Cytomegalovirus (CMV) Infection: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Cytomegalovirus (CMV) Infection- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* mRNA-1647: ModernaTX, Inc.
* Mid Stage Products (Phase II)
* Cytomegalovirus vaccine (Triplex): Helocyte
* Early Stage Products (Phase I)
* VBI-1501: VBI Vaccines Inc.
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Cytomegalovirus (CMV) Infection Key Companies
* Cytomegalovirus (CMV) Infection Key Products
* Cytomegalovirus (CMV) Infection- Unmet Needs
* Cytomegalovirus (CMV) Infection- Market Drivers and Barriers
* Cytomegalovirus (CMV) Infection- Future Perspectives and Conclusion
* Cytomegalovirus (CMV) Infection Analyst Views
* Cytomegalovirus (CMV) Infection Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cytomegalovirus-infection-pipeline-outlook-report-2025-key-15-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cytomegalovirus-cmv-infection-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cytomegalovirus Infection Pipeline Outlook Report 2025: Key 15+ Companies and Breakthrough Therapies Shaping the Future Landscape here
News-ID: 4148521 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for Cytomegalovirus
Cytomegalovirus (CMV) Infections Market Massive Growth opportunity Ahead
Introduction
Cytomegalovirus (CMV) is a common herpesvirus that affects people worldwide, often remaining latent in the body and reactivating under immunocompromised conditions. While typically asymptomatic in healthy individuals, CMV can cause severe complications in newborns, transplant recipients, and immunocompromised patients, making it a significant global healthcare burden.
With increasing awareness, advances in antiviral therapies, vaccines under development, and transplant-related CMV management, the CMV infections market is experiencing strong growth. The integration of…
Cytomegalovirus Retinitis Market Forecast 2031: Growth and Opportunities
The "Cytomegalovirus Retinitis Market" is a dynamic and rapidly evolving sector, with significant advancements and growth anticipated by 2031. Comprehensive market research reveals a detailed analysis of market size, share, and trends, providing valuable insights into its expansion. This report delves into segmentation and definition, offering a clear understanding of market components and drivers. Employing SWOT and PESTEL analyses, the study evaluates the market's strengths, weaknesses, opportunities, and threats, alongside…
Cytomegalovirus Solutions Soar: Cytomegalovirus Treatment Market Targets US$ 326 …
The Cytomegalovirus (CMV) Treatment Market stands at the forefront of addressing a formidable viral adversary that often operates under the radar. Cytomegalovirus, a member of the herpesvirus family, can pose serious threats to individuals with weakened immune systems, such as transplant recipients and those living with HIV. As a result, the development of effective treatments has become a critical endeavor in the realm of infectious diseases.
In 2022, the global cytomegalovirus…
Cytomegalovirus Treatment Market Will Generate Record Revenue by 2029
The global cytomegalovirus treatment market is anticipated to grow at a CAGR of 30.1% during the forecast period (2023-2030). Cytomegalovirus is one of the most common and serious post-transplant infections and can lead to loss of transplanted organ and failure of graft. It has a global estimated incidence rate of 16.0%-56.0% in SOT recipients and 30.0%-70.0% in HSCT recipients.More than 34,000 SOTs and more than 48,000 HSCTs were performed in…
Cytomegalovirus Diagnostics Market Research Insights, Trends Forecast 2022-28
The global cytomegalovirus diagnostics market size was valued at USD 73.6 million in 2021, growing at a CAGR of 6.1% during the forecast period 2022-28. A common herpesvirus called cytomegalovirus can produce a wide range of symptoms, from little to no symptoms to fever and tiredness to severe symptoms affecting the brain, eyes, and other internal organs. Plasma, sperm, saliva, urinalysis, and breast milk can all be used as…
Cytomegalovirus (CMV) Test Market to Develop Rapidly by 2026
Cytomegalovirus (CMV) is a common virus that occurs widely among the population. In the U.S., 50%-85% of adults have been infected with cytomegalovirus (CMV). Most people who are infected with the virus do not experience any significant symptoms or health problems. CMV testing involves either a measurement of cytomegalovirus antibodies, immune proteins produced in response to CMV exposure, or the detection of the virus itself. CMV is found in many…
